Advertisement

Authors' Reply to “Underlying Differences in the Treatment of Left Ventricular Thrombus With Non-Vitamin K Antagonist Oral Anticoagulants”

      We appreciate Leow et al comments
      • Leow AS
      • Sia CH
      • Tan BY
      • Chan MY
      • Loh JP
      Underlying differences in the treatment of left ventricular thrombus with non-vitamin K antagonist oral anticoagulants.
      regarding our recent publication in the AJC, which evaluated the efficacy of direct acting oral anticoagulants (DOAC) in treatment of left ventricular (LV) thrombus.
      • Fledderman AM
      • Hayes CH
      • Magalski A
      • Main ML
      Efficacy of direct acting oral anticoagulants in the treatment of left ventricular thrombus.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leow AS
        • Sia CH
        • Tan BY
        • Chan MY
        • Loh JP
        Underlying differences in the treatment of left ventricular thrombus with non-vitamin K antagonist oral anticoagulants.
        Am J Cardiol. 2019; https://doi.org/10.1016/j.amjcard.2019.07.001
        • Fledderman AM
        • Hayes CH
        • Magalski A
        • Main ML
        Efficacy of direct acting oral anticoagulants in the treatment of left ventricular thrombus.
        Am J Cardiol. 2019; 124: 367-372
        • Dewilde WJ
        • Oirbans T
        • Verheugt FW
        • Kelder JC
        • De Smet BJ
        • Herrman JP
        • Adriaenssens T
        • Vrolix M
        • Heestermans AA
        • Vis MM
        • Tijsen JG
        • van't Hof AW
        • ten Berg JM
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • Gibson CM
        • Mehran R
        • Bode C
        • Halperin J
        • Verheugt FW
        • Wildgoose P
        • Birmingham M
        • Ianus J
        • Burton P
        • van Eickels M
        • Korjian S
        • Daaboul Y
        • Lip GY
        • Cohen M
        • Husted S
        • Peterson ED
        • Fox KA
        Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
        N Engl J Med. 2016; 375: 2423-2434
        • Lopes RD
        • Heizer G
        • Aronson R
        • Vora AN
        • Massaro T
        • Mehran R
        • Goodman SG
        • Windecker S
        • Darius H
        • Li J
        • Averkov O
        • Bahit MC
        • Berwanger O
        • Budaj A
        • Hijazi Z
        • Parkhomenko A
        • Sinnaeve P
        • Storey RF
        • Thiele H
        • Vinereanu D
        • Granger CB
        • Alexander JH
        Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
        N Engl J Med. 2019; 380: 1509-1524
        • Cannon CP
        • Bhatt DL
        • Oldgren J
        • Lip GYH
        • Ellis SG
        • Kimura T
        • Maeng M
        • Merkely B
        • Zeymer U
        • Gropper S
        • Nordaby M
        • Kleine E
        • Harper R
        • Manassie J
        • Januzzi JL
        • Ten Berg JM
        • Steg PG
        • Hohnloser SH
        Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
        N Engl J Med. 2017; 377: 1513-1524